The mineralocorticoid receptor antagonist eplerenone reduces renal interstitial fibrosis after long-term cyclosporine treatment in rat: Antagonizing cyclosporine nephrotoxicity

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Nielsen, Finn Thomsen ^a,b   Jensen, Boye L ^a   Hansen, Pernille B L ^a   Marcussen, Niels ^c   Bie, Peter ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Rigshospitalet   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Aldosterone; Calcineurin; Hypertension; Nephrotoxicity; Renin

Indexed keywords

CYCLOSPORIN A; EPLERENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; ATTENUATION; CONTROLLED STUDY; GLOMERULUS FILTRATION RATE; INDWELLING CATHETER; INULIN CLEARANCE; KIDNEY FIBROSIS; LONG TERM CARE; MALE; NEPHROTOXICITY; NONHUMAN; POTASSIUM BLOOD LEVEL; PRESSURE MEASUREMENT; QUANTITATIVE ANALYSIS; RAT; SODIUM BLOOD LEVEL; STEREOLOGY; WEIGHT GAIN;

ANIMALS; CYCLOSPORINE; DRUG INTERACTIONS; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LONGITUDINAL STUDIES; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NEPHRITIS, INTERSTITIAL; RATS; RATS, SPRAGUE-DAWLEY; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84873966799     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-42     Document Type: Article

References (25)

1. Long-term cyclosporine nephrotoxicity in the rat. Effects on renal function and morphology. Dieperink H, Leyssac PP, Starklint H, Kemp E, Nephrol Dial Transplant 1988 3 3 317 326 3140107
2. Nephrotoxicity of FK506 in the rat. Studies on glomerular and tubular function, and on the relationship between efficacy and toxicity. Nielsen FT, Leyssac PP, Kemp E, Starklint H, Dieperink H, Nephrol Dial Transplant 1995 10 3 334 340 7540737
3. The influence of enalapril or spironolactone on experimental cyclosporine nephrotoxicity. McAuley FT, Whiting PH, Thomson AW, Simpson JG, Biochem Pharmacol 1987 36 5 699 703 10.1016/0006-2952(87)90721-0 3030332 (Pubitemid 17026087)
4. Reduced nephrotoxicity and hepatotoxicity in cyclosporine A therapy by enalapril and spironolactone in rats. Iacona A, Rossetti A, Filingeri V, Orsini D, Cesarini A, Cervelli V, Adorno D, Casciani CU, Drugs Exp Clin Res 1991 17 10-11 501 506 1841039
5. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Feria I, Pichardo I, Juarez P, Ramírez V, González MA, Uribe N, García-Torres R, López-Casillas F, Gamba G, Bobadilla NA, Kidney Int 2003 63 1 43 52 10.1046/j.1523-1755.2003. 00707.x 12472767 (Pubitemid 35463905)
6. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Pérez-Rojas J, Blanco JA, Cruz C, Trujillo J, Vaidya VS, Uribe N, Bonventre JV, Gamba G, Bobadilla NA, Am J Physiol Renal Physiol 2007 292 1 131 139 16835406
7. Effects of spironolactone in an experimental model of chronic cyclosporine nephrotoxicity. Macunluoglu B, Arikan H, Atakan A, Tuglular S, Ulfer G, Cakalagaoglu F, Ozener C, Akoglu E, Transplant Proc 2008 40 1 273 278 10.1016/j.transproceed.2007.11.025 18261605 (Pubitemid 351186626)
8. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporine A nephrotoxicity in conscious rat. Nielsen FT, Jensen BL, Marcussen N, Skott O, Bie P, Nephrol Dial Transplant 2008 23 9 2777 2783 10.1093/ndt/gfn204 18424460
9. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Burgess ED, Lacourcière Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S, Roniker B, Maurath C, Clin Ther 2003 25 9 2388 2404 10.1016/S0149-2918(03)80282- 5 14604739 (Pubitemid 37267247)
10. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG, Kidney Int 2003 63 5 1791 1800 10.1046/j.1523-1755.2003.00929.x 12675855 (Pubitemid 36513325)
11. Uridine adenosine tetraphosphate affects contractility of mouse aorta and decreases blood pressure in conscious rats and mice. Hansen PB, Hristovska A, Wolff H, Vanhoutte P, Jensen BL, Bie P, Acta Physiol 2010 200 2 171 179 10.1111/j.1748-1716.2010.02135.x
12. A new method of measuring renal function in conscious rats without the use of radioisotopes. Gabel RA, Ranaei RA, Kivlighn SD, J Pharmacol Toxicol Methods 1996 36 4 189 197 10.1016/S1056-8719(96)00112-8 9040109 (Pubitemid 27081431)
13. An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin I trapping by antibody. Poulsen K, Jorgensen J, J Clin Endocrinol Metab 1974 39 5 816 825 10.1210/jcem-39-5-816 4370699
14. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, APMIS 1988 96 5 379 394 3288247
15. Interstitial capillary changes in lithium nephropathy: effects of antihypertensive treatment. Skyum H, Marcussen N, Nielsen SH, Christensen S, APMIS 2004 112 10 686 697 10.1111/j.1600-0463.2004.apm1121007.x 15601320 (Pubitemid 40101154)
16. Hyperinsulinemic rats are normotensive but sensitized to angiotensin II. Johansson ME, Andersson IJ, Alexanderson C, Skott O, Holmäng A, Bergström G, Am J Physiol Regul Integr Comp Physiol 2008 294 4 1240 R1247 10.1152/ajpregu.00493.2007 18216141 (Pubitemid 351490644)
17. Circadian rhythm of the renin-angiotensin-aldosterone system in the rat. Hilfenhaus M, Arch Toxicol 1976 36 3-4 305 316 1036902 (Pubitemid 8007225)
18. The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice. Gumz ML, Stow LR, Lynch IJ, Greenlee MM, Rudin A, Cain BD, Weaver DR, Wingo CS, J Clin Invest 2009 119 8 2423 2434 10.1172/JCI36908 19587447
19. Nifedipine attenuates changes in nitric oxide levels, renal oxidative stress, and nephrotoxicity induced by cyclosporine. Chander V, Chopra K, Ren Fail 2005 27 4 441 450 16060134 (Pubitemid 40993695)
20. Amelioration of cyclosporine nephrotoxicity by irbesartan, a selective AT1 receptor antagonist. Chander V, Singh D, Tirkey N, Chander H, Chopra K, Ren Fail 2004 26 5 467 477 10.1081/JDI-200031731 15526904 (Pubitemid 39363277)
21. Loss of calcineurin Aalpha results in altered trafficking of AQP2 and in nephrogenic diabetes insipidus. Gooch JL, Guler RL, Barnes JL, Toro JJ, J Cell Sci 2006 119 Pt 12 2468 76 16735444 (Pubitemid 44070428)
22. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kurtz A, Della Bruna R, Kühn K, Kidney Int 1988 33 5 947 53 10.1038/ki.1988.92 3292818
23. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat. Nielsen FT, Ottosen P, Starklint H, Dieperink H, Nephrol Dial Transplant 2003 18 3 491 496 10.1093/ndt/18.3.491 12584269 (Pubitemid 36305652)
24. Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Shihab FS, Yi H, Bennett WM, Andoh TF, Kidney Int 2000 58 3 1174 1185 10.1046/j.1523-1755.2000.00273.x 10972680
25. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Pérez-Rojas J, Derive S, Blanco JA, Cruz C, Martínez dela Maza L, Gamba G, Bobadilla NA, Am J Physiol Renal Physiol 2005 289 5 1020 1030 10.1152/ajprenal.00166.2005 (Pubitemid 41447057)